The Danish pharmaceutical company Novo Nordisk announced that the medication semaglutide demonstrated effectiveness in reducing obesity in children. The announcement was made based on the results of a phase 3 clinical trial, which is the last stage of testing before seeking regulatory approval.
The study showed that 40.4% of children treated with the medication no longer met the obesity criterion after a period of 68 weeks of treatment. This result represents a significant reduction in the body weight of the children participating in the trial.
Semaglutide is a medication already approved for the treatment of obesity in adults and works as an analog of the GLP-1 hormone, which helps control appetite and blood sugar. The positive results of this trial in children may lead to the expansion of the medication's use to this age group.
